A successful pilot program has lead to a commercial arrangement for Cognetivity Neurosciences (CSE: CGN). The firm this morning revealed that its previously announced pilot program with PRIME Health has lead to the agreement.
Based in the United Arab Emirates, PRIME Health is said to be a leading healthcare services provider in the region. The firm currently has multiple clinics, pharmacies, diagnostics centers and multi-specialty hospitals in the Dubai, Sharjah and Ajman regions of the country. The network as a whole services over 5,000 patients on a daily basis.
The new commercial arrangement with PRIME will see Cognetivity’s Integrated Cognitive Assessment tool, known as CognICA, deployed across the firms network, with compensation to be provided on a pay per use basis. The tool is to be utilized to regularly and accurately assess the brain health of clients, while also screening for anxiety in corporate settings and early detection of cognitive impairments.
“We’re excited to see continued commercial growth as we migrate to a full deployment of CognICA™ with Prime and its clinicians in the UAE, having proven the value of our technology in another highly-sophisticated clinical environment,” commented Dr Sina Habibi, CEO.
The use of the tool is expected to result in improved screening for mental and cognitive impairments, while improving the quality of life for patients.
Financial details of the arrangement were not provided.
Cognetivity Neurosciences last traded at $0.23 on the CSE.
FULL DISCLOSURE: Cognetivity Neurosciences Ltd is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Cognetivity Neurosciences Ltd on The Deep Dive, with The Deep Dive having full editorial control. We may buy or sell securities in the company at any time. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
